Most people who stop semaglutide regain roughly 60% of the weight they lost within a year, according to pooled trial data. Some net loss usually remains compared to where you started, but most of the medication’s effect fades without it. Individual results vary widely based on dose, duration, and lifestyle changes, so talk to your prescriber before stopping or tapering.
TL;DR:
- Most people regain roughly 60% of the weight lost during semaglutide treatment within a year after stopping the medication.
- The fastest weight regain occurs in the first five to six months, with about 60% regained by 52 weeks off the drug, and a plateau around 75% of initial loss.
- Discontinuation leads to appetite signals returning, gastric emptying speeding up, and metabolic defenses that favor weight regain.
- Implementing a taper, increasing physical activity, maintaining high protein intake, and ongoing monitoring can help mitigate early weight regain.
- Structured follow-up and support, including medical tapering and behavioral strategies, are essential to sustain long-term weight management after stopping semaglutide.
The clearest picture of semaglutide weight regain comes from a nonlinear meta-regression published in eClinicalMedicine, which pooled data across multiple GLP-1 discontinuation studies. The researchers modeled regain as an exponential recovery curve, similar to how a stretched rubber band snaps back toward its resting shape rather than all at once.
By 52 weeks off the drug, the model shows patients regaining about 60% of the weight they had lost during treatment. The curve doesn’t stop there. It projects a plateau around 75% of lost weight regained, meaning a meaningful chunk of the original loss can stick permanently for many patients, even without continued treatment. The half-life on that recovery curve lands near 23 weeks, so the fastest regain happens in the first five to six months, then slows.
Trial-level data tells a similar but distinct story. In the STEP 1 extension study, 327 participants stopped semaglutide 2.4 mg after 68 weeks of treatment. By week 120, roughly a year later, they had regained an average of 11.6 percentage points of the weight they’d lost. That still left them at a net loss of 5.6% below their starting body weight, which means the drug’s benefit didn’t vanish completely, it just eroded substantially.
A 2026 systematic review and meta-analysis in BMJ modeled regain trends across weight-management medications broadly and projected an approximate regain rate of 0.4 kg per month in the months following cessation. That’s a useful rule of thumb for pacing expectations, though it’s a modeled average, not a guarantee for any one person.
Here’s how the numbers stack up across the key data points:
The regain curve is front-loaded. Most of it happens in the first six to twelve months after stopping. If you make it past that window with intact habits, the rate of regain tends to slow considerably, which is exactly why the first year after discontinuation matters more than any other stretch.
Weight regain after stopping semaglutide isn’t a cliff, it’s a slope that steepens early and flattens later. That shape has real implications for planning: it argues for closer monitoring right after stopping, not months down the line once the trend is already established.
The trial and review data behind these figures deserve a closer look, because the details shape how much weight you should put on any single number.
The STEP 1 extension followed adults with overweight or obesity who received once-weekly subcutaneous semaglutide 2.4 mg for 68 weeks as part of the original trial. Roughly a third of participants were followed after treatment stopped, tracked out to week 120, giving researchers a full year of off-drug data. The strength of this study is that it’s a randomized controlled trial with a defined dose and duration. The limitation is that it studied one specific dose in a controlled setting with structured counseling, conditions that don’t always match what happens when a real-world patient stops therapy without the same support structure.
The eClinicalMedicine meta-regression took a broader approach, pooling data across separate studies of GLP-1 receptor agonist discontinuation and fitting a mixed-effect exponential recovery model to the combined trajectory. The plateau estimate of 75.3% (95% confidence interval, 68.9 to 81.6%) reflects a modeled ceiling, not an observed endpoint every patient reaches. Confidence intervals that wide tell you there’s real variation between individuals and between studies, which matters more than the headline number in some ways.
The BMJ 2026 review took yet another angle, examining regain after stopping any weight-management medication, not just semaglutide specifically, and generating monthly regain projections. Broadening the population strengthens the case that GLP-1 weight regain isn’t a semaglutide-specific quirk. It reflects how bodies respond to the withdrawal of any effective weight-management therapy.
Three caveats are worth holding onto:
Pro Tip: If your clinician quotes you a specific “you’ll regain X%” number, ask whether that figure comes from a modeled projection or an observed trial outcome. Both are useful, but they answer slightly different questions, and a maintenance plan should account for that difference.
None of this undercuts the core finding. Across three independent lines of evidence, a trial extension, a cross-study meta-regression, and a broader systematic review, the direction and rough magnitude of semaglutide weight regain point the same way: substantial regain is the norm, not the exception, when treatment stops without a follow-up plan.
Semaglutide works by mimicking a gut hormone called GLP-1, which slows gastric emptying and signals fullness to the brain earlier and more strongly than usual. Patients often describe this as their “food noise” going quiet, that constant background hum of thinking about the next meal simply fades. According to Harvard Health’s guidance on transitioning off GLP-1 medications, that quieting effect is exactly what tends to reverse, often within weeks, once the drug clears your system.
Several mechanisms drive the rebound:
There’s also a cardiometabolic angle that matters beyond the scale. Improvements in blood sugar control, blood pressure, and cholesterol that show up during treatment can drift back toward pre-treatment levels as weight returns. This is why regain isn’t just a cosmetic concern. It has real downstream effects on the health markers semaglutide was arguably prescribed to improve in the first place, and it’s a strong argument for continued lab monitoring even after you’ve stopped the medication.
Limiting weight regain isn’t about willpower. It’s about replacing what the drug was doing with strategies that don’t depend on a prescription. Here’s what the evidence supports.
Pro Tip: Start planning your transition two to three months before you actually stop treatment, not the week of. Use that window to build the exercise and protein habits you’ll need, so they’re already routine by the time the appetite suppression fades.
The common thread across all seven strategies is timing. Every one of them works better when it starts before cessation rather than after regain has already begun.
Walking into that conversation with a specific list beats a vague “what should I expect” question. Ask directly:
Bring your own tracking data to that visit if you have it. Weight trends over the prior few months, activity logs, and food tracking history give your clinician far more to work with than a single number on a single day. Regular monitoring also catches the cardiometabolic slide (rising blood pressure or blood sugar) before it becomes a bigger problem, and clinics that manage semaglutide prescriptions long-term generally have a monitoring cadence built into follow-up visits already.
Semaglutide weight regain is predictable enough that it shouldn’t catch anyone off guard, yet most people stop treatment without a monitoring plan in place. AM Rx’s telehealth model exists specifically to close that gap: virtual consults, ongoing prescription management, and scheduled follow-up visits designed around exactly the kind of tapering and maintenance decisions this article covers. A provider who’s tracking your weight trend and labs over time can catch early regain before it becomes a ten-pound problem.
None of this replaces a real conversation with your own prescriber about your specific health history. What it offers is a structured, accessible way to have that conversation regularly instead of once a year.
— Bryan
Stopping semaglutide without a follow-up plan is how most of the regain described above actually happens. There are services that provide a structured alternative: virtual visits with providers who can build tapering schedules, evaluate whether a low-dose maintenance regimen fits your situation, and track the labs and weight trends important in the first critical year off treatment.
Typical visits may start with a review of treatment history and goals, followed by a discussion of options such as continuing at a reduced dose, transitioning to behavioral support, or planning a monitored discontinuation. Prescriptions, when appropriate, can ship directly to the patient, and follow-up visits may be scheduled as part of the process. If you’re weighing whether to keep going, taper, or stop semaglutide altogether, book a telehealth consult and get a specific plan instead of a guess. Check your insurance coverage ahead of time, and always loop in your existing care team on any medication changes.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Most people regain a substantial portion of lost weight, about 60% within a year according to pooled trial data, though a meaningful net loss often remains compared to your starting weight.
Semaglutide quiets constant hunger signals and food-related thoughts by slowing gastric emptying and boosting satiety hormones, an effect many patients describe as their appetite finally going quiet.
Not necessarily, but stopping without a maintenance plan, whether that’s tapering, structured behavioral support, or a low-dose regimen, makes regain far more likely based on current trial evidence.
There’s no strong evidence that semaglutide permanently resets your metabolic set point; most cardiometabolic improvements and appetite suppression effects tend to fade once treatment stops, which is why ongoing monitoring matters.
